As payers increasingly challenge the gap between trial data and real-world outcomes, defending premium oncology pricing requires more than clinical evidence — it demands transparency. This case study explores how a global pharmaceutical leader partnered with QUANTUM to deploy a Real-World Evidence framework that protected premium pricing, eliminated payer uncertainty, and accelerated first-line therapy status by six months.
How Real-World Evidence Defended Premium Oncology Pricing: A Market Access Case Study
The Challenge
A global pharmaceutical leader launched a breakthrough oncology therapy. Despite superior Phase III trial results, national payers in Europe were demanding a 30% discount, citing "uncertainty" in real-world clinical settings compared to controlled trials. The client risked losing millions in annual revenue and faced a potential "price-anchor" that would affect their global launch.
The Solution
- We implemented a Real-World Evidence (RWE) Hub to bridge the data gap.
- Automated Data Integration: We built a secure pipeline to ingest anonymized patient data from participating hospital EHRs (Electronic Health Records).
- Risk-Sharing Framework: We designed an "Outcome-Based Contract" where the client agreed to a "pay-for-performance" model. If the therapy didn't meet specific survival milestones in the real world, the hospital received a rebate.
- Executive Dashboard: We provided payers with a real-time dashboard to monitor therapy efficacy across the patient population, removing the "data black box."
The Impact
-
- Price Protection: The client successfully defended their premium price, avoiding the 30% discount.
- Market Access: Secured "First-Line" therapy status 6 months earlier than projected.
- Scalability: The RWE framework was adopted as the global standard for all future oncology launches within the firm.
